Expression of a novel immunoglobulin gene SNC73 in human cancer and non-cancerous tissues

Table 1 SNC73 expression level in human cancerous tissues and non-cancerous tissues (Mean ± SD). The expression level of SNC73 in both cancerous tissues and non-cancerous tissues was expressed as the ratio of its OD value relative to that of β-actin. (^-x±s)

Tumor	n	SNC73 expression level		Non-cancerous tissues/Cancerous tissues
		Non-cancerous tissues	Cancerous tissues
CRC	31	1.234 ± 0.842	0.737 ± 0.731a	7.134 ± 14.092
Gastric cancer	24	1.098 ± 0.413	1.069 ± 0.606	1.438 ± 1.392
Breast cancer	15	1.279 ± 1.705	0.900 ± 0.690	1.836 ± 2.541
Lung cancer	11	0.834 ± 0.533	1.428 ± 1.904	0.877 ± 0.469
Liver cancer	9	0.793 ± 0.285	0.799 ± 0.322	1.140 ± 0.467

^aP < 0.01 vs non-cancerous tissues.

Table 2 The relationship between SNC73 expression level and various clinicopathological factors of CRC patients. The expression level of SNC73 was interpreted as the ratio of its OD value relative to that of β-actin. (^-x±s)

Factor	Group	n	SNC73 expression level		Non-cancerous tissues/Cancerous tissues
			Non-cancerous tissues	Cancerous tissues
Sex	Male	15	1.360 ± 1.011	0.748 ± 0.438	8.822 ± 18.358
	Female	16	1.116 ± 0.657	0.726 ± 0.943	5.551 ± 8.782
Age	< 60	14	1.524 ± 0.979	0.737 ± 0.458	9.444 ± 18.843
	≥ 60	17	0.995 ± 0.644	0.736 ± 0.911	5.231 ± 8.681
Site	Rectal	17	1.209 ± 0.715	0.616 ± 0.497	10.890 ± 18.260
	Colon	14	1.264 ± 1.002	0.883 ± 0.942	2.572 ± 2.652
Grade of differentiation	Well	14	1.284 ± 1.034	0.756 ± 0.430	2.378 ± 2.488
	Moderately	12	1.188 ± 0.746	0.776 ± 1.086	14.030 ± 21.033
	Poorly	5	1.203 ± 0.536	0.587 ± 0.358	3.898 ± 4.226
Depth of invasion	Mucosa or muscle	8	1.258 ± 0.847	0.973 ± 1.233	9.066 ± 20.511
	Serosa or beyond	23	1.226 ± 0.859	0.654 ± 0.467	6.462 ± 11.624
Metastases	Positive	22	1.225 ± 0.914	0.638 ± 0.479	6.672 ± 11.854
	Negative	9	1.257 ± 0.682	0.977 ± 1.144	8.263 ± 19.334